Rigel Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)

About Rigel Pharmaceuticals INC

Rigel Pharmaceuticals, Inc. (ticker: RIGL) is a U.S.-listed biotechnology company trading on the NASDAQ in the United States. Headquartered in South San Francisco, California, and founded in 1996, Rigel has evolved from a research-driven biotech into a commercial-stage company focused on hematologic disorders and cancer. For French-speaking investors, the company represents a classic U.S. specialty biotech profile: commercially active, pipeline-oriented, and still dependent on clinical execution, label expansion, and sustained product uptake. ([rigel.com](https://www.rigel.com/investors/news-events/press-releases/detail/436/rigel-reports-first-quarter-2026-financial-results?utm_source=openai)) Rigel’s business model centers on three marketed products: TAVALISSE (fostamatinib), GAVRETO (pralsetinib), and REZLIDHIA (olutasidenib). TAVALISSE is the company’s long-standing commercial anchor and is used in certain immune thrombocytopenia settings; GAVRETO is an oncology precision medicine asset targeting RET-driven cancers; and REZLIDHIA addresses specific hematologic indications. In addition to direct product sales, Rigel also generates collaboration revenue through partnerships, royalties, and drug supply arrangements, which helps broaden its revenue base beyond pure U.S. commercialization. ([rigel.com](https://www.rigel.com/investors/news-events/press-releases/detail/436/rigel-reports-first-quarter-2026-financial-results?utm_source=openai)) From a competitive standpoint, Rigel operates in highly specialized therapeutic niches where clinical differentiation, access, and physician adoption matter more than scale alone. That positioning gives it some defensibility, but it also means the company competes against much larger pharmaceutical groups and better-capitalized specialty biotechs with deeper commercial infrastructure. In practical terms, Rigel’s investment case hinges on maintaining sales momentum in approved products while advancing pipeline assets that could extend the franchise over time. ([rigel.com](https://www.rigel.com/investors?utm_source=openai)) Geographically, Rigel remains primarily U.S.-anchored in both listing and operations, but it has an international footprint through commercialization and collaboration agreements with partners in other markets. The latest company updates indicate ongoing commercial traction as well as continued development efforts, particularly around R289, its Phase 1b program in lower-risk myelodysplastic syndrome. ([rigel.com](https://www.rigel.com/investors/news-events/press-releases/detail/436/rigel-reports-first-quarter-2026-financial-results?utm_source=openai)) Recent milestones have been supportive. In March 2026, Rigel announced publication of final ARROW clinical trial data for GAVRETO in RET-positive non-small cell lung cancer in the Journal of Clinical Oncology. In May 2026, the company reported first-quarter 2026 results showing higher net product sales and net income, and it reaffirmed full-year 2026 revenue guidance of approximately $275 million to $290 million. For equity investors, these developments suggest improving operating leverage and a business that is increasingly less reliant on a single clinical catalyst, while still retaining the upside and risk profile typical of a focused biotech company. ([rigel.com](https://www.rigel.com/investors/news-events/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial?utm_source=openai))